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Alarming increase in NAFLD in China
Obesity is a growing health problem in Asian countries including 
China, where the obesity rate has doubled in the last 2 decades. 
As a consequence, the incidence of NAFLD is rapidly rising. 
Wong et al. performed a large prospective cohort study in Hong 
Kong, using state-of-the-art non-invasive methods. The incidence 
of NAFLD at 3-5 years was 13.5%, although few patients 
developed significant fibrosis. This important study highlights 
the current burden of NAFLD in China and also confirms 
previous data that liver fibrosis progresses slowly into fatty liver 
disease. While the incidence of NAFLD is growing, there is an 
urgent need to develop specific therapies for patients with 
non-alcoholic steatohepatitis (NASH) who are at a high risk 
of disease progression. LIVER FIBROSIS
Intrahepatic myeloid 
cells, histone marks, 
and hepatic stellate cell 
activation
Two studies provide new 
insights into the mechanisms 
of hepatic stellate cell (HSC) 
activation, which is a crucial 
event for the initiation of liver 
fibrosis. Chen et al. show that 
the S100 calcium binding protein 
A4 (S100A4) is produced by 
liver myeloid cells (mainly 
macrophages) and activates 
HSCs. In patients with liver 
fibrosis, higher S100A4 levels in 
the liver and peripheral blood, 
correspond to a higher amount 
of fibrosis. 
Tian et al. show in HSCs 
that the MKL/myocardin-like 
protein 1 (also known as 
MRTF-A) recruits a histone 
methyltransferase complex to 
“fibrogenic” gene promoters 
(analogue of the S. cerevisiae 
Set1/COMPASS complex) that 
induces di- and trimethylation 
of histone H3 at lysine 4 
(H3K4me2 and H3K4me3, 
respectively). As these histone 
modifications are known to be 
associated with active genes, 
these studies identify targets for 
novel anti-fibrotic therapies.
LIVER CANCER
Role of protein kinases 
and accuracy of 
contrast-enhanced 
ultrasound
Three studies explore the link 
between inflammation or cell 
metabolism and hepatocellular 
carcinoma (HCC). Cubero et al. 
suggest that in animal models 
the gene Mapk8 (alias Jnk1), 
encoding a mitogen-activated 
Jun kinase, has a synergistic 
function in haematopoietic 
cells and hepatocytes, and is 
involved in the development 
of chronic liver injury and liver 
cancer. 
Zhang et al., by investigating 
hepatitis B-related hepatocellular 
carcinomas bearing p53 
mutations, show that cases that 
exhibit evidence of activation 
in both SIRT1 (a class III 
histone deacetylase) and 
AMP-activated protein kinase 
(AMPK) are associated with 
better outcomes than those 
without SIRT1 and AMPK 
activation. Data are consistent 
with AMPK being located 
downstream of SIRT1 in the 
cascade of events. Beneficial 
effects of AMPK activation 
could be mediated by mTOR 
inhibition. Interestingly the 
fact that activation of AMPK 
with metformin “rescues” p53-
deficient cell lines with inactive 
SIRT1 suggests that use of 
“personalized” metformin 
therapy should be evaluated in 
selected cases of HCC. 
The study by Li et al. reveals 
that autophagy is increased 
in “tumour-associated” 
neutrophils, resulting in 
sustained survival and pro-
tumorigenic effects of these 
cells in human HCC. These 
findings identify a new player 
(i.e., neutrophils) in the tumour 
environment as possible target 
for future therapies. 
Forner et al. show that the 
absence of contrast hyper-
enhancement during the 
arterial phase at contrast-
enhanced ultrasound (CEUS) 
in nodules <2 cm in a cirrhotic 
liver does not predict a 
less malignant profile. They 
conclude that priority for the
diagnostic work-up and treatment 
should not differ according to 
the contrast profile at CEUS.
NON-ALCOHOLIC LIVER 
DISEASE (NAFLD)
Epidemiology, N-3 
polyunsaturated fatty 
acid replacement, and 
sortilin
Argo et al. investigated the 
histological and metabolic 
effects of n-3 polyunsaturated 
fatty acids (n-3 PUFAs), which 
are deficient in patients, 
and have been shown 
to have cardioprotective 
effects. Although N-3 PUFA 
supplementation did not improve 
histological features of NASH, 
it markedly reduced liver fat 
accumulation. These promising 
results suggest that long-term 
dietary supplementation with 
polyunsaturated fatty acids 
may be beneficial, and that a 
detailed nutritional assessment 
in patients with NASH may be 
part of patients’ work-out in the 
future.   
Despite these promising results, 
more specific therapies that 
target key molecular drivers 
in NAFLD are warranted. 
The experimental study by 
Rabinowich et al. shed light 
on a new potential player: 
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sortilin. Sortilin traffics newly 
synthesized molecules from the 
Golgi apparatus and regulates 
ceramide levels by modulating 
acid sphingomyelinases. 
Using a model of diet-induced 
NAFLD, the authors provide 
evidence that sortilin plays 
a role in the development of 
NAFLD by increasing ceramide 
production. This intriguing study 
suggests that proteins regulating 
ceramides could represent a 
potential target to treat fatty liver 
diseases. 
VIRAL HEPATITIS
BE-LOW, HALT-C, 
cryoglobulinemia, and 
T cells
Dynamics of HBsAg levels 
during NUC treatment 
examined in the BE-LOW 
study by Zoulim et al. showed 
a strong correlation with 
HBeAg status, ALT levels 
and HBV genotype A. These 
findings may open the field for 
a more personalized treatment 
approach, in which timing 
of therapy may become an 
important issue. 
The combination of telbivudine 
with pegylated interferon 
increases the overall antiviral 
efficacy but is also modifying the 
side effect profile of telbivudine. 
This is the lesson we learn 
from the study by Marcellin et 
al. evaluating the safety and 
efficacy of telbivudine plus 
pegylated interferon alfa-2a in 
a randomized study.
The so far largest evaluation of 
safety and efficacy of the first 
generation protease inhibitor 
triple regimen for HCV-mixed 
cryoglobulinemic vasculitis 
was performed by Saadoun et 
al., demonstrating the potential 
benefits of the regimen but also 
emphasizing the risks for those 
with advanced fibrosis and low 
platelet counts.
A significant reduction in the 
risk of fibrosis progression 
among statin users with 
advanced chronic hepatitis C 
was described by Simon, King 
and co-workers by performing 
a post hoc analysis of the 
HALT-C trial. However, given 
the small number of statin users, 
the importance of the study is 
mainly due to paving the way for 
future studies, validating these 
findings.
By using new bioinformatics 
tools, Losikoff et al. describe a 
unique viral peptide, derived 
from the HCV p7 protein that 
promotes an inhibitory Treg 
cell response that cross-reacts 
with HLA-matched peptide 
sequences, located within 
hundreds of human proteins, 
hereby probably downregulating 
immune function and inducing 
HCV tolerance. 
Reversing T cell exhaustion 
by targeting inhibitory co-
regulatory molecules could 
provide a promising approach for 
restoring effective immunological 
control over persistent viral 
infections. However, highly 
variable inter-individual 
response patterns, observed by 
Sekyere and co-workers after 
antibody-mediated manipulation 
of the co-regulatory receptor 
signalling, will challenge its 
clinical development.
CIRRHOSIS
Brain function, 
inflammation, 
transplantation 
preconditioning and 
ischemia reperfusion 
injury
The complications of cirrhosis 
are the main reason for hospital 
admission and the occurrence 
of hepatic encephalopathy 
and infection/inflammation are 
important determinants of in-
hospital mortality. The study 
of Ahluwalia et al. and the 
associated Editorial highlights 
that treating hyponatraemia 
is more than just treating a 
result and provides human 
evidence for the improvement 
of cognitive function and the 
reduction in brain oedema, 
following treatment of 
hyponatraemia. 
The study by Lozano-Ruiz et 
al. provides novel evidence to 
suggest that the inflammasome 
is highly activated in the 
ascitic fluid, mediated by the 
protein absent in melanoma 
2 (AIM2), which has recently 
been described as the first non-
NLR (nucleotide-binding domain 
leucine-rich repeat) receptor 
that induces inflammasome 
activation. This may have 
important implications in 
understanding the pathobiology 
of inflammation in liver failure. 
The paper by Jiménez-Castro et 
al. describes important studies 
in rats, which show that the 
addition of acetylcholine to 
the well-known protective 
effects of preconditioning 
may be highly protective 
to improve graft function for 
organs obtained from brain 
dead donors. This study has the 
potential for clinical translation. 
Important observations from 
Wang et al. provide further 
insights into the pathogenesis 
of hepatic ischemia reperfusion 
injury from studies in knock-
out mice, which suggest that 
interferon regulatory factor 9 
(IRF-9) is a key regulator of 
ischemia reperfusion injury 
and may well be a future target 
of therapy. 
The study by Sharma and 
colleagues provides important 
new insights into the role 
of hepatogenic microRNAs 
in their ability to induce 
hepatocyte differentiation of 
embryonic stem cells. They 
identified an important role 
for miR-199a-5p. Its inhibition 
in human embryonic stem cell-
derived hepatocyte-like cells 
increased the engraftment 
and repopulation capacity in 
immunodeficient mice. The data 
suggest that mIR modulation is 
an important target to generate 
more mature hepatocyte-like 
cells from embryonic stem cells. 
Lluis-Castells et al. provide 
important new data for therapy 
of post-transplant HIV/HCV 
co-infected patients with 
interferon and ribavirin. 
They make the important 
observation of a significantly 
lower virological response 
in co-infected patients 
(21%) compared with mono-
infected patients (36%; p = 
0.01). However, patients 
that responded had excellent 
survival. These data justify trials 
of the new direct-acting antiviral 
drugs in this population.
SPLANCHNIC VEIN 
THROMBOSIS
A new mutation 
A study by García-Pagán and 
colleagues describes that 
in patients with portal vein 
thrombosis or Budd-Chiari 
syndrome, 5.4% of patients 
with myeloproliferative 
diseases that are negative for 
the common JAK2 mutation 
carry somatic mutations 
in the calreticulin (CALR) 
gene (encoding a protein 
specific for the endoplasmic 
reticulum). They emphasize that 
a stepwise assessment may 
improve the diagnostic yield 
of myeloproliferative diseases 
and reduce the need for other 
diagnostic studies.
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